EY acquires Greek life sciences consulting business Aqurance

Big Four firm EY has acquired Aqurance, a Veeva Premier Services Partner based in Greece.

Established in 2011, Aqurance is a provider of clinical, commercial and digital transformation services to clients in the life sciences and pharma sector. The firm has about 65 employees.

With the acquisition of Aqurance, EY expands its expertise in Veeva applications in both commercial and research & development (R&D), as well as regulatory transformation and platform integration. The bolt-on also strengthen EY’s Veeva Centers of Excellence, which operates worldwide.

Dan Mathews, Global Life Sciences Leader at EY, said: “This is a pivotal moment for the industry as life sciences companies make critical decisions about platform migration, compliance and data integration. With the acquisition of Aqurance, EY can offer clients a more integrated pathway – strategy through execution – to unlock the full power of Veeva technology. Together, we will help companies move faster, stay compliant and use data and AI to help drive more informed decisions.”

For Aqurance, the joining of forces with the global consulting giant will enhance its services to clients and offer its team members with expanded project and career development opportunities.

“By joining EY, we’re gaining access to a global network and world class capabilities,” said Dionissis Nikolopoulos, Founder & CEO of Aqurance. “This partnership allows us to do more of what we love: being the trusted partner that guides life science businesses to excel in research, commercialization, and digital transformation.”

The deal

Aqurance was advised during the deal by TH Healthcare and Life Sciences, a division of TH Global Capital, which acted as the exclusive financial advisor to the Greek business.

Financial terms and conditions of the deal have not been disclosed.